Super proud of the team's achievement 🚀
Shipping our second model Latent-X2 that allows users to design antibody binders on our platform. Check the below thread for more details 👇
5 months from Latent-X1 to Latent-X2. AI-generated antibodies with drug-like developability and low immunogenicity in human panels — zero-shot.
Available now for selected partners.
Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end.
Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert.
Technical report: https://t.co/E7IHfkvvD3
Blog post: https://t.co/GfJAfzj0Qx
Apply for access: https://t.co/E0SR9znZiP
Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot.
Technical report: https://t.co/9uU6GQCdM7
Blog: https://t.co/TFyCzlZ4qN
Apply for access: [email protected]
5 months from Latent-X1 to Latent-X2. AI-generated antibodies with drug-like developability and low immunogenicity in human panels — zero-shot.
Available now for selected partners.
Latent-X has been available for a little over two weeks, and we couldn't be more excited about the science that is already being done with it on our platform.
Our CEO @saakohl joined @Bloomberg News Daybreak Europe this morning to talk about why we're building it, and the impact it is already having.
Watch the video here: https://t.co/ZhCiNYaBgh
Showcasing Latent-X's breakthrough macrocycle designs.
Our AI achieved an unprecedented 91-100% hit rate with single-digit micromolar binding affinities—functional binders on every single target tested.
Explore our binders without logging in: https://t.co/y3rt7xJ9AP
The first 3 days have been incredible.
The response from our research community has been phenomenal. Many hundreds of users, tens of thousands of designs and amazing feedback flowing in.
🧬 Latent-X is our first frontier model for protein design.
For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.
Explore our best binders here (no login required): https://t.co/MF3zseHg2k
More details on the breakthrough in this🧵
5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design.
Available now on our no-code platform!
Really happy to be releasing our first model on a beautiful platform. It generates de novo binders with impressive affinity and speed. If you are curious, you can try it for yourself, more info on the thread👇
Introducing Latent-X — our all-atom frontier AI model for protein binder design.
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: https://t.co/NamdznPWjL
Blog: https://t.co/2UkYDEe8a9
Technical report: https://t.co/0m2s3y7vwN
Introducing Latent-X — our all-atom frontier AI model for protein binder design.
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: https://t.co/NamdznPWjL
Blog: https://t.co/2UkYDEe8a9
Technical report: https://t.co/0m2s3y7vwN
@Latent_Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design.
Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can play - but not all are in a position to develop their own advanced models. That’s where @Latent_Labs comes in.
Excited by the generality of CLIP, but need more fine-grained details in your representation? Introducing SPARC, a simple and scalable method for pretraining multimodal representations with fine-grained information. 🥳 1/6
I'm very excited to share our papers that have been accepted at @aistats_conf2024! This year, we keep pushing our research on reality-centric AI - from advancing scientific discovery and adaptive experimental design to data-centric AI. Some amazing technical work by my students!
Un rêve de pouvoir enfin porter les couleurs de la @KarmineCorp au plus haut niveau et d'écrire un nouveau chapitre pour l'organisation.
Rendez-vous dans 10 jours #KCORP
Always a pleasure to engage with the ML community at conferences! Had an amazing time at #NeurIPS2023 and really interesting conversations with researchers from all around the world. Really worth arguing with Reviewer 2 🤩
Had an amazing time at #NeurIPS where we discovered that if you forget to take your poster down you may end up doing a whole second poster session the following morning feat. @JonathanICrabbe with an (appropriately?!) guilty expression 😅
🚨Tomorrow (Wednesday) at 5pm #NeurIPS 🚨
If you are interested in ensembles, MoEs, optimisation, vision, or memes come visit myself & @JonathanICrabbe at poster #537!